Tactile Medical has announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available across the US for expanded indication.

Nimbl is intended for the treatment of upper and lower extremity lymphedema.

Following its October 2024 launch for upper extremity lymphedema, the pneumatic compression platform is now also available for treating lower extremity conditions, including phlebolymphedema.

Tactile Medical CEO Sheri Dodd said: “On the heels of Nimbl’s launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 million Americans with chronic swelling in the lower extremities.

“These patients require effective, convenient therapies to help manage their symptoms. With Nimbl, they now have access to a solution which embodies patient-focused innovation and reflects our commitment to serving patients and improving their care experience.”

Nimbl is a 60-minute daily pneumatic compression device (PCD) designed to relieve lymphedema.

It uses a gentle squeezing action to move lymphatic fluid away from the affected area, guiding it toward healthy regions for natural absorption and elimination.

The device is said to be the smallest pneumatic compression device (PCD), with a compact controller that is 68% lighter and 40% smaller than Tactile Medical’s existing PCD.

According to the medical technology company, the device’s lower extremity garment uses 94% less hosing, making it easy to transport and manage.

It weighs under two pounds and features a simple two-button interface for easy operation.

The controller, about the size of a hardcover book, is easy to store or pack in an overnight bag.

Tactile Medical said Nimbl provides a comfortable treatment with unique inflation and deflation, maintaining clinical effectiveness. Active deflation allows for quick garment removal, making it easy to store and resume daily activities.

Additionally, the pneumatic compression platform is said to be the only basic PCD with Bluetooth connectivity, allowing patients to track treatments and progress using the free Kylee app.

It secured the US Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval in September last year.